##semicolon##
multiple sclerosis, neuroinflammation, progressive MS, immunotherapy, neurofilaments, PIRA, personalized medicine.##submission.citations##
1. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Annals of Neurology. 2004;55(4):458-468.
2. Bar-Or A., Bittner S., Cross A.H., et al. BTK inhibitors in multiple sclerosis: emerging concepts. Neurology. 2023;100(3):121-130.
3. Bar-Or A., Montalban X., Patti F., et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a phase 2 trial. Lancet Neurology. 2025;24(8):656-666.
4. Barro C., Benkert P., Disanto G., et al. Serum neurofilament as a predictor of disease worsening in multiple sclerosis. JAMA Neurology. 2018;75(1):79-87.
5. Bjornevik K., Cortese M., Healy B.C., et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301.
6. Boyko A.N., Gusev E.I. Evolution of multiple sclerosis therapy: from escalation to early high-efficacy therapy. Nervous Diseases. 2024;(1):12-20. (In Russian)
7. Chitnis T., Kuhle J., Barro C., et al. Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications. Lancet Neurology. 2025;24(12):1066-1078.
8. Filippi M., Rocca M.A., Barkhof F., et al. Artificial intelligence applied to MRI in multiple sclerosis. Brain. 2024;147(2):435-452.
9. Hauser S.L., Cree B.A.C. Treatment of multiple sclerosis: A review. JAMA. 2020;323(8):765-779.
10. Kappos L., Fox R.J., Burcklen M., et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis. JAMA Neurology. 2021;78(5):558-567.
11. Kappos L., Wolinsky J.S., Giovannoni G., et al. Progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. 2020;26(10):1236-1245.
12. Lyutov O.V., Kutlubaev M.A., Kuzmina U.S., et al. Impact of multiple sclerosis on life expectancy: a review. Neurology Bulletin. 2025;57(4):321-330.
13. Montalban X., Hauser S.L., Kappos L., et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine. 2017;376(3):209-220.
14. Nimerchy M.A., Knyazeva A.I., Novikov V.M., et al. Modern aspects of immunomodulatory therapy of multiple sclerosis. Bulletin of the Pirogov National Medical and Surgical Center. 2025;20(4):118-122. (In Russian)
15. Ochilova D., Majidova Y.N. Features of the course of multiple sclerosis in the Uzbek population. Iqtidorli yoshlarning ilmiy ishlari va XXI asr tibbiyoti. 2023;1(1):160. (In Uzbek)
16. Rakhmattulaeva G.K., Kadirova A.Sh. (2026). THE ROLE OF MOLECULAR-GENETIC MARKERS OF THROMBOPHILIA IN THE DEVELOPMENT OF ISCHEMIC STROKE IN WOMEN OF DIFFERENT AGE GROUPS. Central Asian Journal of Medicine, 1(8), 123-131.
17. Rashidova N.S., Salimjonov J.J. (2026). COMPREHENSIVE ASSESSMENT OF NEUROLOGICAL COMPLICATIONS FOLLOWING COVID-19 VACCINATION. Central Asian Journal of Medicine, 1(11), 286-292.
18. Shamansurov Sh.Sh., Gulyamova M.K., Karimova N.A. Clinical features of pediatric multiple sclerosis. Doktor axborotnomasi. 2022;2.3(105):47-50. (In Russian)
19. Thompson A.J., Banwell B.L., Barkhof F., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology. 2018;17(2):162-173.
20. Traka M., Kim J., Kiraly D., et al. Oligodendrocytes Are Active Participants in the Pathogenesis of Multiple Sclerosis and Its Animal Models. International Journal of Molecular Sciences. 2026;27(4):1779.
21. Turuspekova S.T., Nurguzhaev E.S., Kaishibaeva G.S. Epidemiology of multiple sclerosis in Kazakhstan and Central Asian countries. Neurosurgery and Neurology of Kazakhstan. 2024;(1):33-41. (In Russian)
22. Walton C., King R., Rechtman L., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal. 2023;29(8):928-942.
23. Yakubova M.M., Khalimova Kh.M., Parpieva Yu.R. Clinical and neurological aspects of multiple sclerosis during COVID-19 infection in Uzbekistan. Central Asian Journal of Medical and Natural Science. 2021;2(3):186-190. (In Russian)
24. Yunusova M.R., Rakhimbaeva G.S. Review of early clinical manifestations of multiple sclerosis. Journal of Education and Scientific Medicine. 2024;1(6):81-86. (In Russian)
25. Zavalishin I.A., Peresedova A.V., Sivertseva S.A. Immunopathogenesis of multiple sclerosis: current state of the problem. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2023;123(7):7-15. (In Russian)